Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.51 |
| ▸ | SCN1A | P35498 | 2/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.42 |
| ▸ | HRH1 | P35367 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17069296 | 1.00 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL17069299 | 1.00 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| Ammonia Solution, Strong SCHEMBL6267830 | 0.98 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL23046611 | 0.91 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL725091 | 0.86 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL28985177 | 0.86 | SLC6A3 (0.47) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL28985174 | 0.86 | SLC6A3 (0.47) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL18596651 | 0.85 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL15470472 | 0.84 | CHRM2 (0.55) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL20385395 | 0.84 | SLC6A3 (0.46) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511294-B1 | METHOD FOR STORING AND DISCHARGING HYDROGEN USING PYRIDINE-BASED HYDROGEN STORAGE MATERIAL | KOREA RES INST CHEMICAL TECH (KR) | 2022-06-15 | — | — | EP | claimed |
| US-20150303390-A1 | SEQUENCE DEPENDENT ASSEMBLY TO CONTROL MOLECULAR INTERFACE PROPERTIES FOR MEMORY DEVICES, SOLAR CELLS AND MOLECULAR DIODES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-10-22 | — | — | US | claimed |
| EP-2909871-A2 | SEQUENCE DEPENDENT ASSEMBLY TO CONTROL MOLECULAR INTERFACE PROPERTIES FOR MEMORY DEVICES, SOLAR CELLS AND MOLECULAR DIODES | Yeda Research and Development Co. Ltd (IL) | 2015-08-26 | — | — | EP | claimed |
| WO-2014061018-A2 | SEQUENCE DEPENDENT ASSEMBLY TO CONTROL MOLECULAR INTERFACE PROPERTIES FOR MEMORY DEVICES, SOLAR CELLS AND MOLECULAR DIODES | YEDA RESEARCH AND DEVELOPMENT CO. LTD AT THE WEIZMANN INSTITUTE OF SCIENCE (IL) | 2014-04-24 | — | — | WO | claimed |
| CN-101396363-A | Composite antibacterial drugs composition containing abafungin | CHONGQING PHARMACEUTICAL RESEA (CN) | 2009-04-01 | — | — | CN | claimed |
| CN-1531541-A | Rhodium and iridium complexes | �����л��뵼������˾ | 2004-09-22 | — | — | CN | claimed |
| US-12612566-B2 | Methods of processing, transporting, or both, of hydrogen | SAUDI ARABIAN OIL COMPANY (SA) | 2026-04-28 | — | — | US | disclosed |
| WO-2025136903-A1 | METHODS OF PROCESSING, TRANSPORTING, OR BOTH, OF HYDROGEN | SAUDI ARABIAN OIL COMPANY (SA) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025136901-A1 | METHODS OF PROCESSING, TRANSPORTING, OR BOTH, OF HYDROGEN | SAUDI ARABIAN OIL COMPANY (SA) | 2025-06-26 | — | — | WO | disclosed |
| US-20250197744-A1 | METHODS OF PROCESSING, TRANSPORTING, OR BOTH, OF HYDROGEN | SAUDI ARABIAN OIL COMPANY (SA) | 2025-06-19 | — | — | US | disclosed |
| US-20250197740-A1 | METHODS OF PROCESSING, TRANSPORTING, OR BOTH, OF HYDROGEN | SAUDI ARABIAN OIL COMPANY (SA) | 2025-06-19 | — | — | US | disclosed |
| US-12137605-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION | 2024-11-05 | — | — | US | disclosed |
| US-12038650-B2 | Multilayer phase difference plate, polarizing plate, and image display device | ZEON CORPORATION (JP) | 2024-07-16 | — | — | US | disclosed |
| CN-1200694-C | Solid medicaments obtained by extrusion of isomalt-containing polymer-active substance melt | BASF AG (DE) | 2005-05-11 | — | — | CN | disclosed |
| CN-1531541-A | Rhodium and iridium complexes | �����л��뵼������˾ | 2004-09-22 | — | — | CN | disclosed |
| EP-1073430-A1 | USE OF NMDA ANTAGONISTS AND/OR SODIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | AstraZeneca AB (SE) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055322-A1 | USE OF NMDA ANTAGONISTS AND/OR SODIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ASTRAZENECA AB (SE) | 1999-11-04 | — | — | WO | disclosed |
| CN-1198094-A | Solid medicaments obtained by extrusion of isomalt-containing polymer-active substance melt | BASF AG (DE) | 1998-11-04 | — | — | CN | disclosed |
| EP-0770065-A1 | TRI-SUBSTITUTED PHENYL DERIVATES USEFUL AS PDE IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-05-02 | — | — | EP | disclosed |
| WO-1995035281-A1 | TRI-SUBSTITUTED PHENYL DERIVATES USEFUL AS PDE IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12137605-B2 | Organic electroluminescent materials and devices | TSHR, GLRA3, GLRB | SLC6A2 1988/4885SLC6A4 667/4885SLC6A3 1053/4885 |
| US-12038650-B2 | Multilayer phase difference plate, polarizing plate, and image display device | RAD1, RPAP1, RPA1 | SLC6A2 3153/4885SLC6A4 3324/4885SLC6A3 3929/4885 |
| US-12612566-B2 | Methods of processing, transporting, or both, of hydrogen | C9, AHR, ARNT | SLC6A2 213/4885SLC6A4 140/4885SLC6A3 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.